VII

EQS-News: Deutsche Beteiligungs AG: Sale of investment in Cloudflight

Retrieved on: 
Friday, November 11, 2022

Deutsche Beteiligungs AG (DBAG) has very successfully concluded its investment in Cloudflight, a leading european full-service provider for digital transformation, selling its stake to Partners Group, a leading global private markets firm, acting on behalf of its clients.

Key Points: 
  • Deutsche Beteiligungs AG (DBAG) has very successfully concluded its investment in Cloudflight, a leading european full-service provider for digital transformation, selling its stake to Partners Group, a leading global private markets firm, acting on behalf of its clients.
  • Through its investment in Cloudflight, DBAG FundVII had structured smooth succession arrangements for the founder-led business.
  • The sale of the Cloudflight investment is the second disposal of a management buyout (MBO) from DBAGFundVIIs portfolio.
  • Deutsche Beteiligungs AG (DBAG) has been listed since 1985 and is one of most renowned private equity firms in Germany.

Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101

Retrieved on: 
Thursday, November 3, 2022

Abeona anticipates submitting results from this study, including further details with additional exploratory endpoints and the Week 12 results, for presentation at future medical meetings and for publication in a peer-reviewed journal.

Key Points: 
  • Abeona anticipates submitting results from this study, including further details with additional exploratory endpoints and the Week 12 results, for presentation at future medical meetings and for publication in a peer-reviewed journal.
  • The Week 12 results are similar to Week 24 results, achieving statistical significance for pain reduction and wound healing at all levels.
  • In the Phase 3 VIITAL study, EB-101 has been shown to both heal such large chronic wounds and significantly reduce pain.
  • Abeona Therapeutics will host a conference call and webcast on Thursday, November 3, 2022, at 8:30 a.m. EDT, to discuss the positive topline results from the VIITAL study.

Austere Pushes the Boundaries of Surge Protection AGAIN - A First Look at Austere's VII, V, and III Series Wall-Mount Power Devices

Retrieved on: 
Wednesday, November 2, 2022

PORTLAND, Ore., Nov. 2, 2022 /PRNewswire/ -- Austere, a leading manufacturer of premium A/V accessories, cables, and Clean & Protect™, is introducing a line of full-featured, low-profile 4-outlet surge protectors. Designed to fit discreetly in the tightest of spaces, near furniture, or behind wall-mounted TVs, Austere's new VII Series ($129.99), V Series ($99.99), and III Series ($79.99) sit flush with the wall for an elegant and unobtrusive appearance.

Key Points: 
  • Austere Introduces New Range of Feature-Rich Surge Protection Devices Featuring AC Line-Noise Filtering, Ultra-Fast Power Delivery (PD), and USB Charging, Beautifully Designed, with Safety in Mind.
  • Austere's signature three blue LED lights ensure power, proper grounding, and surge protection.
  • Austere surge protectionregulates the power coming from the outside powerline which guarantees devices will not burn out from a high voltage spike that can be harmful to your equipment.
  • The V Series and VII Series include Power Delivery (PD) USB ports, the quickest, most efficient way to charge compatible devices.

Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Retrieved on: 
Wednesday, October 19, 2022

NEW YORK and CLEVELAND, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the database lock on October 18, 2022 for the pivotal Phase 3 VIITAL study of its investigational autologous, engineered cell therapy, EB-101, in patients with recessive dystrophic epidermolysis bullosa (RDEB).

Key Points: 
  • NEW YORK and CLEVELAND, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the database lock on October 18, 2022 for the pivotal Phase 3 VIITAL study of its investigational autologous, engineered cell therapy, EB-101, in patients with recessive dystrophic epidermolysis bullosa (RDEB).
  • EB-101 is an autologous, engineered cell therapy currently being investigated in Abeonas pivotal Phase 3 VIITAL study for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder without an approved therapy.
  • Abeona produces EB-101 for the VIITAL study at its fully integrated gene and cell therapy manufacturing facility in Cleveland, Ohio.
  • Abeonas lead clinical program is EB-101, its investigational autologous, engineered cell therapy for recessive dystrophic epidermolysis bullosa is in Phase 3 development.

NASA Orders Three More Orion Spacecraft from Lockheed Martin

Retrieved on: 
Thursday, October 20, 2022

DENVER, Oct. 20, 2022 /PRNewswire/ -- Lockheed Martin (NYSE: LMT) is now under contract to deliver three Orion spacecraft to NASA for its Artemis VI-VIII missions, continuing the delivery of exploration vehicles to the agency to carry astronauts into deep space and around the Moon supporting the Artemis program.

Key Points: 
  • "Lockheed Martin is honored to partner with NASA to deliver Orion spacecraft for NASA's Artemis missions.
  • This order includes spacecraft, mission planning and support, and takes us into the 2030s," said Lisa Callahan, vice president and general manager for Commercial Civil Space, Lockheed Martin.
  • A breakout of these orders includes:
    2022: NASA orders three additional Orion spacecraft missions for Artemis VI-VIII for $1.99 billion.
  • Under OPOC, Lockheed Martin and NASA have reduced the costs on Orion by 50% per vehicle on Artemis III through Artemis V, compared to vehicles built during the design and development phase.

Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Retrieved on: 
Tuesday, October 4, 2022

We thank the patients, their families, and the clinical investigators, and plan to report topline results from this pivotal study within the next month.

Key Points: 
  • We thank the patients, their families, and the clinical investigators, and plan to report topline results from this pivotal study within the next month.
  • EB-101 is an autologous, engineered cell therapy currently being investigated in Abeonas pivotal Phase 3 VIITAL study for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder without an approved therapy.
  • Abeona produces EB-101 for the VIITAL study at its fully integrated gene and cell therapy manufacturing facility in Cleveland, Ohio.
  • Abeonas lead clinical program is EB-101, its investigational autologous, engineered cell therapy for recessive dystrophic epidermolysis bullosa is in Phase 3 development.

Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa

Retrieved on: 
Wednesday, September 21, 2022

PITTSBURGH, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the European Medicines Agency (EMA) Pediatric Committee (PDCO) has adopted a positive opinion on the Pediatric Investigation Plan (PIP) for beremagene geperpavec (B-VEC) for the treatment of dystrophic epidermolysis bullosa.

Key Points: 
  • PITTSBURGH, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the European Medicines Agency (EMA) Pediatric Committee (PDCO) has adopted a positive opinion on the Pediatric Investigation Plan (PIP) for beremagene geperpavec (B-VEC) for the treatment of dystrophic epidermolysis bullosa.
  • The positive opinion is based on the B-VEC non-clinical safety program as well as data from the clinical studies conducted in the US that will be included in the upcoming MAA.
  • The U.S. Food and Drug Administration (FDA) and EMA have each granted B-VEC orphan drug designation for the treatment of DEB.
  • The FDA has granted B-VEC fast track designation, Regenerative Medicine Advanced Therapy (RMAT) and rare pediatric disease designation for the treatment of DEB.

Club dVIN Announces Historic Opportunity to Participate in Bhutan's First Wine Harvest

Retrieved on: 
Monday, September 19, 2022

THIMPHU, Bhutan, Sept. 19, 2022 /PRNewswire/ -- Club dVIN, the world's premier global non-fungible token (NFT) wine club, has announced an unprecedented opportunity for oenophiles to participate in one of a series of weeklong excursions during Bhutan's first wine grape harvest. Spanning 10 weeks from late July through late September 2023, each of the trips will host 15 members.

Key Points: 
  • Tasting Token NFTs, created with technology proprietary to Club dVIN, are minted when bottles attached to a Club dVIN Digital Cork NFT are opened.
  • More information about Club dVIN is available on the website as well as on Club dVIN's Instagram and Twitter channels.
  • Daily content is posted on Club dVIN's Discord , including wine discussions and weekly events around all things wine and crypto.
  • The world's premier global non-fungible token (NFT) wine club, Club dVIN provides access to a global community of wine lovers, rare wine offerings and curated experiences.

Club dVIN Announces Historic Opportunity to Participate in Bhutan's First Wine Harvest

Retrieved on: 
Monday, September 19, 2022

THIMPHU, Bhutan, Sept. 19, 2022 /PRNewswire/ -- Club dVIN, the world's premier global non-fungible token (NFT) wine club, has announced an unprecedented opportunity for oenophiles to participate in one of a series of weeklong excursions during Bhutan's first wine grape harvest. Spanning 10 weeks from late July through late September 2023, each of the trips will host 15 members.

Key Points: 
  • Tasting Token NFTs, created with technology proprietary to Club dVIN, are minted when bottles attached to a Club dVIN Digital Cork NFT are opened.
  • More information about Club dVIN is available on the website as well as on Club dVIN's Instagram and Twitter channels.
  • Daily content is posted on Club dVIN's Discord , including wine discussions and weekly events around all things wine and crypto.
  • The world's premier global non-fungible token (NFT) wine club, Club dVIN provides access to a global community of wine lovers, rare wine offerings and curated experiences.

Global Vehicle Emission Sensor Market to Reach $4.9 Billion by 2027

Retrieved on: 
Thursday, September 1, 2022

DUBLIN, Sept. 1, 2022 /PRNewswire/ -- The "Global Vehicle Emission Sensor Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 1, 2022 /PRNewswire/ -- The "Global Vehicle Emission Sensor Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global vehicle emission sensor market is projected to grow at a CAGR of 2.01% during the forecast period to reach US$4.496 billion by 2027, from US$3.911 billion in 2020.
  • The ever-increasing demand for automobiles and the alarming increase in pollution has significantly fuelled the vehicle emission sensor market.
  • Furthermore, the increasingly stringent emission norms and surging penetration of diesel vehicles have also propelled the automotive exhaust sensor market growth.